Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-669899f699-tzmfd Total loading time: 0 Render date: 2025-05-05T11:34:52.302Z Has data issue: false hasContentIssue false

Chapter 31 - Medication in Pregnancy (Content last reviewed: 11th November 2020)

from Section 5 - Late Pregnancy – Maternal Problems

Published online by Cambridge University Press:  15 November 2017

By
Carl P. Weiner  and
Clifford W. Mason
Edited by
David James ,
Philip Steer ,
Carl Weiner ,
Bernard Gonik  and
Stephen Robson
David James
Affiliation:
University of Nottingham
Philip Steer
Affiliation:
Imperial College London
Carl Weiner
Affiliation:
University of Kansas
Bernard Gonik
Affiliation:
Wayne State University, Detroit
Stephen Robson
Affiliation:
University of Newcastle
Get access

Summary

Drug use during pregnancy and lactation remain underdeveloped areas of clinical pharmacology and drug research. Pregnancy risk factors together with an increased incidence of chronic diseases and a rise in the average maternal age predict medication use will continue to rise during gestation. Common exposure categories include over-the-counter (OTC) medication, psychiatric agents, gastrointestinal medications, herbals, vitamins, antibiotics, and topical products. Only a few medications have been tested specifically for safety and efficacy during human gestation. Profound physiologic changes occur during both normal and pathologic pregnancy that may dramatically alter drug clearance, efficacy, and safety. Under such circumstances, the danger of a drug to mothers, their fetuses, and nursing infants cannot be determined with any confidence until it has been widely used. It is important that women with medical disorders such as diabetes, hypertension, epilepsy, and inflammatory bowel disease continue necessary therapy while pregnant. Unfortunately, many physicians stop or delay medically important agents precisely because of the lack of information.

Type
Chapter
Information
High-Risk Pregnancy
Management Options
 , pp. 807 - 845
Publisher: Cambridge University Press
First published in: 2017

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Book purchase

Temporarily unavailable

References

Further Reading

Bleyer, WA, Breckenridge, RT. Studies on the detection of adverse drug reactions in the newborn. II. The effects of prenatal aspirin on newborn hemostasis. JAMA 1970; 213: 2049–53.Google Scholar
Clayton-Smith, J, Donnai, D. Human malformations. In Rimoin, DL, Connor, JM, Pyeritz, RE (eds), Emery and Rimoin’s Principles and Practice of Medical Genetics, 3rd edn. New York, NY: Churchill Livingstone, 1996, p. 383.Google Scholar
Einarson, A, Pistelli, A, DeSantis, M, et al. Evaluation of the risk of congenital cardiovascular defects associated with use of paroxetine during pregnancy. Am J Psychiatry 2008; 165: 749–52.Google Scholar
Holmes, LB. Teratogen-induced limb defects. Am J Med Genet 2002; 112: 297–303.Google Scholar
Marks, PW. Management of thromboembolism in pregnancy. Semin Perinatol 2007; 31: 227–31.Google Scholar
Matheson, I, Samseth, M, Sande, HA. Ampicillin in breast milk during puerperal infections. Eur J Clin Pharmacol 1988; 34: 657–9.Google Scholar
Slone, D, Shapiro, S, Miettinen, O. Case–control surveillance of serious illnesses attributable to ambulatory drug use. In Colombo, F, Shapiro, S, Slone, D, Tognoni, G (eds), Epidemiological Evaluation of Drugs. Amsterdam: Elsevier-North Holland Biomedical, 1977, pp. 59–70.Google Scholar
Spinillo, A, Viazzo, F, Colleoni, R, et al. Two-year infant neurodevelopmental outcome after single or multiple antenatal courses of corticosteroids to prevent complications of prematurity. Am J Obstet Gynecol 2004; 191: 217–24.Google Scholar
Teixeira, NA, Lopes, RC, Secoli, SR. Developmental toxicity of lithium treatment at prophylactic levels. Braz J Med Biol Res 1995; 28: 230–9.Google Scholar
Weiner, CP, Mason, C. Drugs for Pregnant and Lactating Women, 3rd edn. Philadelphia, PA: Churchill Livingstone, 2020.Google Scholar

References

Buhimschi, CS, Weiner, CP. Medications in pregnancy and lactation. In Queenan, JT, Spong, CY, Lockwood, CJ (eds), Management of High Risk Pregnancy. An Evidence Based Approach, 5th edn. Malden, MA: Blackwell, 2007, pp. 38–58.Google Scholar
Plentl, AA, Gray, MJ. Total body water, sodium space and total exchangeable sodium in normal and toxemic pregnant women. Am J Obstet Gynecol 1959; 78: 472–8.Google Scholar
Verkeste, CM, Slangen, BF, Dubelaar, ML, et al. Mechanism of volume adaptation in the awake early pregnant rat. Am J Physiol 1998; 274: H1662–6.Google Scholar
Frederickson, MC. Physiologic changes in pregnancy and their effect on drug distribution. Semin Perinat 2001; 25: 120–3.Google Scholar
Spaanderman, ME, Meertens, M, van Bussel, M, et al. Cardiac output increases independently of basal metabolic rate in early human pregnancy. Am J Physiol Heart Circ Physiol 2000; 278: H1585– 8.Google Scholar
Robson, SC, Hunter, S, Boys, RJ, et al. Serial study of factors influencing changes in cardiac output during human pregnancy. Am J Physiol 1989; 256: H1060–5.Google Scholar
Robson, SC, Mutch, E, Boys, RJ, et al. Apparent liver blood flow during pregnancy: a serial study using indocyanine green clearance. Br J Obstet Gynaecol 1990; 97: 720–4.Google Scholar
Everson, GT. Gastrointestinal motility in pregnancy. Gastroenterol Clin North Am 1992; 21: 751–76.Google Scholar
American College of Obstetrics and Gynecology. Nausea and vomiting of pregnancy (Practice Bulletin No. 52). Obstet Gynecol 2004; 103: 803–14.Google Scholar
Anderson, GD. Using pharmacokinetics to predict the effects of pregnancy and maternal–infant transfer of drugs during lactation. Expert Opin Drug Metab Toxicol 2006; 2: 947–60.Google Scholar
Wood, M, Wood, AJ. Changes in plasma drug binding and alpha 1-acid glycoprotein in mother and newborn infant. Clin Pharmacol Ther 1981; 29: 522–6.Google Scholar
Shepard, TH, Lemire, RJ (eds). Catalog of Teratogenic Agents, 12th edn. Baltimore, MD: Johns Hopkins University Press, 2007.Google Scholar
Chambers, C, Weiner, CP. Teratogenesis and environmental exposure. In Creasy, RK, Resnik, R, Iams, JD, et al. (eds), Creasy & Resnik’s Maternal Fetal Medicine. Principles and Practice, 6th edn. Philadelphia, PA: Saunders Elsevier, 2009, pp. 347–59.Google Scholar
Buhimschi, CS, Weiner, CP. Medications in pregnancy and lactation: Part 1. Teratology. Obstet Gynecol 2009; 113: 166–88.Google Scholar
Clayton-Smith, J, Donnai, D. Human malformations. In Rimoin, DL, Connor, JM, Pyeritz, RE (eds), Emery and Rimoin’s Principles and Practice of Medical Genetics, 3rd edn. New York, NY: Churchill Livingstone, 1996, p. 383.Google Scholar
Cabrera, RM, Hill, DS, Etheredge, AJ, et al. Investigations into the etiology of neural tube defects. Birth Defects Res C Embryo Today 2004; 72: 330–44.Google Scholar
Kozer, E, Nikfar, S, Costei, A, et al. Aspirin consumption during the first trimester of pregnancy and congenital anomalies: a meta-analysis. Am J Obstet Gynecol 2002; 187: 1623–30.CrossRefGoogle ScholarPubMed
Vermillion, ST, Scardo, JA, Lashus, AG, et al. The effect of indomethacin tocolysis on fetal ductus arteriosus constriction with advancing gestational age. Am J Obstet Gynecol 1997; 177: 256–9.Google Scholar
Warkany, J. Warfarin embryopathy. Teratology 1976; 14: 205–9.Google Scholar
Vitale, N, De Feo, M, De Santo, LS, et al. Dose-dependent fetal complications of warfarin in pregnant women with mechanical heart valves. J Am Coll Cardiol 1999; 33: 1637–41.Google Scholar
Kaplan, LC. Congenital Dandy–Walker malformation associated with first trimester warfarin: a case report and literature review. Teratology 1985; 32: 333–7.Google Scholar
Carney, EW, Scialli, AR, Watson, RE, et al. Mechanisms regulating toxicant disposition to the embryo during early pregnancy: an interspecies comparison. Birth Defects Res C Embryo Today 2004; 72: 345–60.Google Scholar
Giroux, M, Teixera, MG, Dumas, JC, et al. Influence of maternal blood flow on the placental transfer of three opioids: fentanyl, alfentanil, sufentanil. Biol Neonate 1997; 72: 133–41.Google Scholar
Ageno, W, Crotti, S, Turpie, AG. The safety of antithrombotic therapy during pregnancy. Expert Opin Drug Saf 2004; 3: 113–18.Google Scholar
Young, AM, Allen, CE, Audis, KL. Efflux transporters of the human placenta. Adv Drug Deliv Rev 2003; 55: 125–32.Google Scholar
Schatz, M. The efficacy and safety of asthma medications during pregnancy. Semin Perinatol 2001; 25: 145–52.Google Scholar
Yerby, M. The use of anticonvulsants during pregnancy. Semin Perinatol 2001; 25: 153–8.Google Scholar
Sibai, BM. Antihypertensive drugs during pregnancy. Semin Perinatol 2001; 25: 159–64.CrossRefGoogle ScholarPubMed
Newport, DJ, Wilcox, MM, Stowe, ZN. Antidepressants during pregnancy and lactation: defining exposure and treatment issues. Semin Perinatol 2001; 25: 145–58.Google Scholar
McCartney, MA, Scinto, PL, Wang, SS, et al. Developmental effects of phenytoin may differ depending on sex of offspring. Neurotoxicol Teratol 1999; 21: 119–28.Google Scholar
Boncinelli, E. Homeobox genes and disease. Curr Opin Genet Dev 1997; 7: 331–7.Google Scholar
Zakany, J, Duboule, D. The role of Hox genes during vertebrate limb development. Curr Opin Genet Dev 2007; 17: 359–66.Google Scholar
Faiella, A, Wernig, M, Consalez, GG, et al. A mouse model for valproate teratogenicity: parental effects, homeotic transformations, and altered HOX expression. Hum Mol Genet 2000; 9: 227–36.Google Scholar
Suzuki, A, Urushitani, H, Sato, T, et al. Gene expression change in the Müllerian duct of the mouse fetus exposed to diethylstilbestrol in utero. Exp Biol Med (Maywood) 2007; 232: 503–14.Google Scholar
Addis, A, Sharabi, S, Bonati, M. Risk classification systems for drug use during pregnancy: are they a reliable source of information? Drug Saf 2000; 23: 245–53.Google Scholar
Weiner CP. Introduction. In Weiner CP, Mason C (eds), Drugs for Pregnant and Lactating Women, 3rd edn. Philadelphia, PA: Saunders Elsevier, 2020.Google Scholar
American College of Obstetricians and Gynecologists. Viral hepatitis in pregnancy (Practice Bulletin No. 86). Obstet Gynecol 2007; 110: 941–56.Google Scholar
Sinclair SM, Jones JK, Miller RK, et al. The Ribavirin Pregnancy Registry: an interim analysis of potential teratogenicity at the mid-point of enrollment. Drug Saf 2017; 40: 1205–18. https://doi.org/10.1007/s40264-017-0566-6.Google Scholar
Chambers, CD, Braddock, SR, Briggs, GG, et al. Postmarketing surveillance for human teratogenicity: a model approach. Teratology 2001; 64: 252–61.Google Scholar
Mitchell, AA. Systematic identification of drugs that cause birth defects: a new opportunity. N Engl J Med 2003; 349: 2556–9.Google Scholar
Kennedy, DL, Uhl, K, Kweder, SL. Pregnancy exposure registries. Drug Saf 2004; 27: 215–228.Google Scholar
Briggs, GG, Polifka, J; Research Committee, Organization of Teratology Information Specialists. Better data needed from pregnancy registries. Birth Defects Res A Clin Mol Teratol 2009; 85: 109–11.Google Scholar
Källén, BA. Methodological issues in the epidemiological study of the teratogenicity of drugs. Congenit Anom (Kyoto) 2005; 45: 44–51.Google Scholar
Slone, D, Shapiro, S, Miettinen, O. Case–control surveillance of serious illnesses attributable to ambulatory drug use. In Colombo, F, Shapiro, S, Slone, D, Tognoni, G (eds), Epidemiological Evaluation of Drugs. Amsterdam: Elsevier-North Holland Biomedical, 1977, pp. 59–70.Google Scholar
Buhimschi, CS, Weiner, CP. Medications in pregnancy and lactation: Part 2. Drugs with minimal or unknown human teratogenic effect. Obstet Gynecol 2009; 113: 417–32.Google Scholar
Landon, MB. Diabetic nephropathy and pregnancy. Clin Obstet Gynecol 2007; 50: 998–1006.Google Scholar
Tomlinson, AJ, Campbell, J, Walker, JJ, et al. Malignant primary hypertension in pregnancy treated with lisinopril. Ann Pharmacother 2000; 34: 180–2.Google Scholar
August, P, Mueller, FB, Sealey, JE, et al. Role of renin–angiotensin system in blood pressure regulation in pregnancy. Lancet 1995; 345: 896–7.Google Scholar
Easterling, TR, Carr, DB, Davis, C, et al. Low-dose, short-acting, angiotensin-converting enzyme inhibitors as rescue therapy in pregnancy. Obstet Gynecol 2000; 96: 956–61.Google Scholar
Tabacova, SA, Kimmel, CA. Enalapril: pharmacokinetic/dynamic inferences for comparative developmental toxicity. A review. Reprod Toxicol 2001; 15: 467–78.Google Scholar
Miller, RK, Jessee, L, Barrish, A, et al. Pharmacokinetic studies of enalaprilat in the in vitro perfused human placental lobule system. Teratology 1998; 58: 76–81.Google Scholar
Burrows, RF, Burrows, EA. Assessing the teratogenic potential of angiotensin-converting enzyme inhibitors in pregnancy. Aust N Z J Obstet Gynaecol 1998; 38: 306–11.Google Scholar
Centers for Disease Control and Prevention (CDC). Postmarketing surveillance for angiotensin-converting enzyme inhibitor use during the first trimester of pregnancy: United States, Canada, and Israel, 1987–1995. MMWR Morb Mortal Wkly Rep 1997; 46: 240–2.Google Scholar
Maliheh, K, Abdorrazagh, K, Armen, K, et al. Angiotensin converting enzyme inhibitors and aortic arch obstructive malformations. Indian J Med Sci 2006; 60: 417–20.Google Scholar
Boix, E, Zapater, P, Picó, A, et al. Teratogenicity with angiotensin II receptor antagonists in pregnancy. J Endocrinol Invest 2005; 28: 1029–31.Google Scholar
Cooper, WO, Hernandez-Diaz, S, Arbogast, PG, et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med 2006; 354: 2443–51.Google Scholar
Laube, GF, Kemper, MJ, Schubiger, G, Neuhaus, TJ. Angiotensin-converting enzyme inhibitor fetopathy: long-term outcome. Arch Dis Child Fetal Neonatal Ed 2007; 92: F402–3.Google Scholar
Redman, CW, Kelly, JG, Cooper, WD. The excretion of enalapril and enalaprilat in human breast milk. Eur J Clin Pharmacol 1990; 38: 99.Google Scholar
Devlin, RG, Fleiss, PM. Captopril in human blood and breast milk. J Clin Pharmacol 1981; 21: 110–13.Google Scholar
American College of Obstetricians and Gynecologists. Use of psychiatric medications during pregnancy and lactation (Practice Bulletin No. 92). Obstet Gynecol 2008; 111: 1001–20.Google Scholar
American College of Obstetricians and Gynecologists. Treatment with selective serotonin reuptake inhibitors during pregnancy (Committee Opinion No. 354). Obstet Gynecol 2006; 108: 1601–3.Google Scholar
Cohen, LS, Altshuler, LL, Harlow, BL, et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA 2006; 295: 499–507.Google Scholar
Reefhuis, J, Devine, O, Friedman, JM, Louik, C, Honein, MA; National Birth Defects Prevention Study. Specific SSRIs and birth defects: Bayesian analysis to interpret new data in the context of previous reports. BMJ 2015; 351: h3190.Google Scholar
Howard, LM, Hoffbrand, S, Henshaw, C, et al. Antidepressant prevention of postnatal depression. Cochrane Database Syst Rev 2005; (2): CD004363.Google Scholar
Heikkinen, T, Ekblad, U, Palo, P, Laine, K. Pharmacokinetics of fluoxetine and norfluoxetine in pregnancy and lactation. Clin Pharmacol Ther 2003; 73: 330–7.Google Scholar
Wen, SW, Yang, Q, Garner, P, et al. Selective serotonin reuptake inhibitors and adverse pregnancy outcomes. Am J Obstet Gynecol 2006; 194: 961–6.Google Scholar
Malm, H, Klaukka, T, Neuvonen, PJ. Risks associated with selective serotonin reuptake inhibitors in pregnancy. Obstet Gynecol 2005; 106: 1289–96.Google Scholar
Einarson, TR, Einarson, A. Newer antidepressants in pregnancy and rates of major malformations: a meta-analysis of prospective comparative studies. Pharmacoepidemiol Drug Saf 2005; 14: 823–7.Google Scholar
Hendrick, V, Stowe, ZN, Altshuler, LL, et al. Placental passage of antidepressant medications. Am J Psychiatry 2003; 160: 993–6.Google Scholar
Louik, C, Lin, AE, Werler, MM, et al. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med 2007; 356: 2675–83.Google Scholar
Bérard, A, Iessa, N, Chaabane, S, et al. The risk of major cardiac malformations associated with paroxetine use during the first trimester of pregnancy: a systematic review and meta-analysis. Br J Clin Pharmacol 2016; 81: 589–604.Google Scholar
Masarwa R, Bar-Oz B, Gorelik E, et al. Prenatal exposure to selective serotonin reuptake inhibitors and serotonin norepinephrine reuptake inhibitors and risk for persistent pulmonary hypertension of the newborn: a systematic review, meta-analysis, and network meta-analysis. Am J Obstet Gynecol 2019; 220: 57.e1–57.e13. https://doi.org/10.1016/j.ajog.2018.08.030.Google Scholar
Einarson, A, Pistelli, A, DeSantis, M, et al. Evaluation of the risk of congenital cardiovascular defects associated with use of paroxetine during pregnancy. Am J Psychiatry 2008; 165: 749–52.Google Scholar
Einarson, A. Risks/safety of psychotropic medication use during pregnancy: Motherisk Update 2008. Can J Clin Pharmacol 2009; 16: e58–65.Google Scholar
Chambers, CD, Johnson, KA, Dick, LM, et al. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 1996; 335: 1010–15.Google Scholar
Bellissima V, Visser GHA, Ververs T, et al. Antenatal maternal antidepressants drugs treatment affects S100B levels in maternal-fetal biological fluids in a dose dependent manner. Clin Chim Acta 2020; 501 :20–6. https://doi.org/10.1016/j.cca.2019.11.027.Google Scholar
Zeskind, PS, Stephens, LE. Maternal selective serotonin reuptake inhibitor use during pregnancy and newborn neurobehavior. Pediatrics 2004; 113: 368–75.Google Scholar
Stowe, ZN, Hostetter, AL, Owens, MJ, et al. The pharmacokinetics of sertraline excretion into human breast milk: Determinants of infant serum concentrations. J Clin Psychiatry 2003; 64: 73–80.Google Scholar
Hendrick, V, Fukuchi, A, Altshuler, L, et al. Use of sertraline, paroxetine and fluvoxamine by nursing women. Br J Psychiatry 2001; 179: 163–6.Google Scholar
Back, DJ, Bates, M, Bowden, A, et al. The interaction of phenobarbital and other anticonvulsants with oral contraceptive steroid therapy. Contraception 1980; 22: 495–503.Google Scholar
Crawford, P, Chadwick, D, Cleland, P, et al. The lack of effect of sodium valproate on the pharmacokinetics of oral contraceptive steroids. Contraception 1986; 33: 23–9.Google Scholar
Crawford, P. Interactions between antiepileptic drugs and hormonal contraception. CNS Drugs 2002; 16: 263–72.Google Scholar
Patsalos, PN, Berry, DJ, Bourgeois, BF, et al. Antiepileptic drugs— Best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 2008; 49: 1239–76.Google Scholar
McAuley, JW, Anderson, GD. Treatment of epilepsy in women of reproductive age: pharmacokinetic considerations. Clin Pharmacokinet 2002; 41: 559–79.Google Scholar
Leppik, IE, Rask, CA. Pharmacokinetics of antiepileptic drugs during pregnancy. Semin Neurol 1988; 8: 240–6.Google Scholar
Eberhard-Gran, M, Eskild, A, Opjordsmoen, S. Treating mood disorders during pregnancy: safety considerations. Drug Saf 2005; 28: 695–706.Google Scholar
Petrenaite, V, Sabers, A, Hansen-Schwartz, J. Individual changes in lamotrigine plasma concentrations during pregnancy. Epilepsy Res 2005; 65: 185–8.Google Scholar
Battino, D, Tomson, T. Management of epilepsy during pregnancy. Drugs 2007; 67: 2727–46.Google Scholar
Franco, V, Mazzucchelli, I, Gatti, G, et al. Changes in lamotrigine pharmacokinetics during pregnancy and the puerperium. Ther Drug Monit 2008; 30: 544–7.Google Scholar
Azarbayjani, F, Danielsson, BR. Embryonic arrhythmia by inhibition of HERG channels: a common hypoxia-related teratogenic mechanism for antiepileptic drugs? Epilepsia 2002; 43: 457–68.Google Scholar
Jäger-Roman, E, Deichl, A, Jakob, S, et al. Fetal growth, major malformations, and minor anomalies in infants born to women receiving valproic acid. J Pediatr 1986; 108: 997–1004.Google Scholar
Kjaer, D, Horvath-Puhó, E, Christensen, J, et al. Antiepileptic drug use, folic acid supplementation, and congenital abnormalities: a population-based case–control study. BJOG 2008; 115: 98–103.Google Scholar
Nakamura, H, Ushigome, F, Koyabu, N, et al. Proton gradient-dependent transport of valproic acid in human placental brush-border membrane vesicles. Pharm Res 2002; 19: 154–61.Google Scholar
Clayton-Smith, J, Donnai, D. Fetal valproate syndrome. J Med Genet 1995; 32: 724–7.Google Scholar
Lindhout, D, Omtzigt, JG, Cornel, MC. Spectrum of neural-tube defects in 34 infants prenatally exposed to antiepileptic drugs. Neurology 1992; 42: 111–18.Google Scholar
Kozma, C. Valproic acid embryopathy: report of two siblings with further expansion of the phenotypic abnormalities and a review of the literature. Am J Med Genet 2001; 98: 168–75.Google Scholar
Witters, I, Van Assche, F, Fryns, JP. Nuchal edema as the first sign of fetal valproate syndrome. Prenat Diagn 2002; 22: 834–5.Google Scholar
Pynnönen, S, Kanto, J, Sillanpää, M, et al. Carbamazepine: placental transport, tissue concentrations in foetus and newborn, and level in milk. Acta Pharmacol Toxicol (Copenh) 1977; 4: 244–53.Google Scholar
Matalon, S, Schechtman, S, Goldzweig, G, et al. The teratogenic effect of carbamazepine: a meta-analysis of 1255 exposures. Reprod Toxicol 2002; 16: 9–17Google Scholar
Moore, SJ, Turnpenny, P, Quinn, A, et al. A clinical study of 57 children with fetal anticonvulsant syndromes. J Med Genet 2000; 37: 489–97.Google Scholar
Webster, WS, Howe, AM, Abela, D, et al. The relationship between cleft lip, maxillary hypoplasia, hypoxia and phenytoin. Curr Pharm Des 2006; 12: 1431–48.Google Scholar
Hanson, JW, Smith, DW. The fetal hydantoin syndrome. J Pediatr 1975; 87: 285–90.Google Scholar
Iqbal, MM, Sohhan, T, Mahmud, SZ. The effects of lithium, valproic acid, and carbamazepine during pregnancy and lactation. J Toxicol Clin Toxicol 2001; 39: 381–92.Google Scholar
Myllynen, PK, Pienimäki, PK, Vähäkangas, KH. Transplacental passage of lamotrigine in a human placental perfusion system in vitro and in maternal and cord blood in vivo. Eur J Clin Pharmacol 2003; 58: 677–82.Google Scholar
Cunnington, M, Ferber, S, Quartey, G; International Lamotrigine Pregnancy Registry Scientific Advisory Committee. Effect of dose on the frequency of major birth defects following fetal exposure to lamotrigine monotherapy in an international observational study. Epilepsia 2007; 48: 1207–10.Google Scholar
Fotopoulou, C, Kretz, R, Bauer, S, et al. Prospectively assessed changes in lamotrigine-concentration in women with epilepsy during pregnancy, lactation and the neonatal period. Epilepsy Res 2009; 85: 60–4.Google Scholar
Chaudron, LH. When and how to use mood stabilizers during breastfeeding. Prim Care Update Ob Gyns 2000; 7: 113–17.Google Scholar
Frey, B, Schubiger, G, Musy, JP. Transient cholestatic hepatitis in a neonate associated with carbamazepine exposure during pregnancy and breast-feeding. Eur J Pediatr 1990; 150: 136–8.CrossRefGoogle Scholar
Shimoyama, R, Ohkubo, T, Sugawara, K, et al. Monitoring of phenytoin in human breast milk, maternal plasma and cord blood plasma by solid-phase extraction and liquid chromatography. J Pharm Biomed Anal 1998; 17: 863–9.Google Scholar
Kessler, RC, Berglund, P, Demler, O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62: 593–602.Google Scholar
Iqbal, MM, Sobhan, T, Ryals, T. Effects of commonly used benzodiazepines on the fetus, the neonate, and the nursing infant. Psychiatr Serv 2002; 53: 39–49.Google Scholar
Belfort, MA, Anthony, J, Saade, GR. Prevention of eclampsia. Semin Perinatol 1999; 23: 65–78.Google Scholar
Duley, L, Gulmezoglu, AM. Magnesium sulphate versus lytic cocktail for eclampsia. Cochrane Database Syst Rev 2001; (1): CD002960.Google Scholar
Duley, L, Henderson-Smart, D. Magnesium sulphate versus diazepam for eclampsia. Cochrane Database Syst Rev 2003; (4): CD000127.Google Scholar
Yaris, F, Kadioglu, M, Kesim, M, et al. Newer antidepressants in pregnancy: Prospective outcome of a case series. Reprod Toxicol 2004; 19: 235–8.Google Scholar
Eros, E, Czeizel, AE, Rockenbauer, M, et al. A population-based case-control teratologic study of nitrazepam, medazepam, tofisopam, alprazolum and clonazepam treatment during pregnancy. Eur J Obstet Gynecol Reprod Biol 2002; 101: 147–54.Google Scholar
Blotière PO, Raguideau F, Weill A, et al. Risks of 23 specific malformations associated with prenatal exposure to 10 antiepileptic drugs. Neurology 2019; 93: e167–80. https://doi.org/10.1212/WNL.0000000000007696.Google Scholar
Lim, EC, Seet, RC, Wilder-Smith, EP, et al. Dystonia gravidarum: a new entity? Mov Disord 2006; 21: 69–70.Google Scholar
Kanto, J, Erkkola, R. The feto-maternal distribution of diazepam in early human pregnancy. Ann Chir Gynaecol Fenn 1974; 63: 489–491.Google Scholar
Saxén, I. Cleft palate and maternal diphenhydramine intake. Lancet 1974; 1: 407–8.Google Scholar
Rosenberg, L, Mitchell, AA, Parsells, JL, et al. Lack of relation of oral clefts to diazepam use during pregnancy. N Engl J Med 1983; 309: 1282–5.Google Scholar
Gonzalez de Dios, J, Moya-Benavent, M, Carratala-Marco, F. “Floppy infant” syndrome in twins secondary to the use of benzodiazepines during pregnancy. Rev Neurol 1999; 29: 121–3.Google Scholar
St. Clair, SM, Schirmer, RG. First-trimester exposure to alprazolam. Obstet Gynecol 1992; 80: 843–6.Google Scholar
García-Algar, O, López-Vílchez, MA, Martín, I, et al. Confirmation of gestational exposure to alprazolam by analysis of biological matrices in a newborn with neonatal sepsis. Clin Toxicol (Phila) 2007; 45: 295–8.Google Scholar
Fisher, JB, Edgren, BE, Mammel, MC, et al. Neonatal apnea associated with maternal clonazepam therapy: a case report. Obstet Gynecol 1985; 66: 34S–35S.Google Scholar
McElhatton, PR. The effects of benzodiazepine use during pregnancy and lactation. Reprod Toxicol 1994; 8: 461–75.Google Scholar
Oo, CY, Kuhn, RJ, Desai, N, et al. Pharmacokinetics in lactating women: prediction of alprazolam transfer into milk. Br J Clin Pharmacol 1995; 40: 231–6.Google Scholar
Kart Koseoglu, H, Yucel, AE, Kunefeci, G, et al. Cyclophosphamide therapy in a serious case of lupus nephritis during pregnancy. Lupus 2001; 10: 818–20.Google Scholar
Ozalp, SS, Yalcin, OT, Tanir, HM. A hospital-based multicentric study results on gestational trophoblastic disease management status in a developing country. Eur J Gynaecol Oncol 2001; 22: 221–2.Google Scholar
Peters, BG, Bray, JJ, Masidonski, P, et al. Issues surrounding adjuvant chemotherapy for breast cancer during pregnancy. Oncol Nurs Forum 2001; 28: 639–42.Google Scholar
Enns, GM, Roeder, E, Chan, RT, et al. Apparent cyclophosphamide (Cytoxan) embryopathy: a distinct phenotype? Am J Med Genet 1999; 86: 237–41.Google Scholar
Meirow, D, Epstein, M, Lewis, H, et al. Administration of cyclophosphamide at different stages of follicular maturation in mice: Effects on reproductive performance and fetal malformations. Hum Reprod 2001; 16: 632–7.Google Scholar
Paskulin, GA, Gazzola Zen, PR, de Camargo Pinto, LL, et al. Combined chemotherapy and teratogenicity. Birth Defects Res A Clin Mol Teratol 2005; 73: 634–7.Google Scholar
Ostensen, M. Treatment with immunosuppressive and disease modifying drugs during pregnancy and lactation. Am J Reprod Immunol 1992; 28: 148–52.Google Scholar
Amato, D, Niblett, JS. Neutropenia from cyclophosphamide in breast milk. Med J Aust 1977; 1: 383–4.Google Scholar
Hammond, MG, Hammond, CB, Parker, RT. Conservative treatment of endometriosis externa: The effects of methyltestosterone therapy. Fertil Steril 1978; 29: 651–4.Google Scholar
Penteado, SR, Fonseca, AM, Bagnoli, VR, et al. Effects of the addition of methyltestosterone to combined hormone therapy with estrogens and progestogens on sexual energy and on orgasm in postmenopausal women. Climacteric 2008; 11: 17–25.Google Scholar
Borgatta, L, Murthy, A, Chuang, C, et al. Pregnancies diagnosed during Depo-Provera use. Contraception 2002; 66: 169–72.Google Scholar
Bianchi, S, Busacca, M, Agnoli, B, et al. Effects of 3 month therapy with danazol after laparoscopic surgery for stage III/IV endometriosis: a randomized study. Hum Reprod 1999; 14: 1335–7.Google Scholar
Shane, BS, Dunn, HO, Kenney, RM, et al. Methyl testosterone-induced female pseudohermaphroditism in dogs. Biol Reprod 1969; 1: 41–8.Google Scholar
Grote, K, Stahlschmidt, B, Talsness, CE, et al. Effects of organotin compounds on pubertal male rats. Toxicology 2004; 202: 145–158.Google Scholar
Tuffli, GA. Testosterone and micropenis. J Pediatr 1974; 84: 927.Google Scholar
Duck, SC, Katayama, KP. Danazol may cause female pseudohermaphroditism. Fertil Steril 1981; 35: 230–1.Google Scholar
Minh, HN, Belaisch, J, Smadja, A. Female pseudohermaphroditism. Presse Med 1993; 22: 1735–40.Google Scholar
Kingsbury, AC. Danazol and fetal masculinization: a warning. Med J Aust 1985; 143: 410–11.Google Scholar
Rosa, FW. Virilization of the female fetus with maternal danazol exposure. Am J Obstet Gynecol 1984; 149: 99–100.Google Scholar
Baheiraei, A, Ardsetani, N, Ghazizadeh, S. Effects of progestogen-only contraceptives on breast-feeding and infant growth. Int J Gynaecol Obstet 2001; 74: 203–5.Google Scholar
Ratchanon, S, Taneepanichskul, S. Depot medroxyprogesterone acetate and basal serum prolactin levels in lactating women. Obstet Gynecol 2000; 96: 926–8.Google Scholar
Kaya, H, Babar, Y, Ozmen, S, et al. Intratubal methotrexate for prevention of persistent ectopic pregnancy after salpingotomy. J Am Assoc Gynecol Laparosc 2002; 9: 464–7.Google Scholar
Kulier, R, Gulmezoglu, AM, Hofmeyr, GJ, et al. Medical methods for first trimester abortion. Cochrane Database Syst Rev 2004; (2): CD002855.Google Scholar
Creinin, MD, Wiebe, E, Gold, M. Methotrexate and misoprostol for early abortion in adolescent women. J Pediatr Adolesc Gynecol 1999; 12: 71–7.Google Scholar
Gracia, CR, Brown, HA, Barnhart, KT. Prophylactic methotrexate after linear salpingostomy: a decision analysis. Fertil Steril 2001; 76: 1191–5.Google Scholar
Dilbaz, S, Caliskan, E, Dilbaz, B, et al. Predictors of methotrexate treatment failure in ectopic pregnancy. J Reprod Med 2006; 51: 87–93.Google Scholar
Yedlinsky, NT, Morgan, FC, Whitecar, PW. Anomalies associated with failed methotrexate and misoprostol termination. Obstet Gynecol 2005; 105: 1203–5Google Scholar
Del Campo, M, Kosaki, K, Bennett, FC, et al. Developmental delay in fetal aminopterin/methotrexate syndrome. Teratology 1999; 60: 10–12.Google Scholar
Sorosky, JI, Sood, AK, Buekers, TE. The use of chemotherapeutic agents during pregnancy. Obstet Gynecol Clin North Am 1997; 24: 591–9.Google Scholar
Ostensen, M, Motta, M. Therapy insight: the use of antirheumatic drugs during nursing. Nat Clin Pract Rheumatol 2007; 3: 400–6.Google Scholar
Koren, G, Soldin, O. Therapeutic drug monitoring of antithyroid drugs in pregnancy: The knowledge gaps. Ther Drug Monit 2006; 28: 12–13.Google Scholar
Azizi, F. The safety and efficacy of antithyroid drugs. Expert Opin Drug Saf 2006; 5: 107–16.Google Scholar
Mestman, JH. Diagnosis and management of maternal and fetal thyroid disorders. Curr Opin Obstet Gynecol 1999; 11: 167–75.Google Scholar
American College of Obstetrics and Gynecology. Thyroid disease in pregnancy (Practice Bulletin No. 37). Int J Gynaecol Obstet 2002; 79: 171–80.Google Scholar
Chattaway, JM, Klepser, TB. Propylthiouracil versus methimazole in treatment of Graves’ disease during pregnancy. Ann Pharmacother 2007; 41: 1018–22.Google Scholar
Takata, K, Kubota, S, Fukata, S, et al. Methimazole-induced agranulocytosis in patients with Graves’ disease is more frequent with an initial dose of 30 mg daily than with 15 mg daily. Thyroid 2009; 19: 559–63.Google Scholar
McNab, T, Ginsberg, J. Use of anti-thyroid drugs in euthyroid pregnant women with previous Graves’ disease. Clin Invest Med 2005; 28: 127–31.Google Scholar
Azizi, F, Khamseh, ME, Bahreynian, M, et al. Thyroid function and intellectual development of children of mothers taking methimazole during pregnancy. J Endocrinol Invest 2002; 25: 586–9.Google Scholar
Messer, PM, Hauffa, BP, Olbricht, T, et al. Antithyroid drug treatment of Graves’ disease in pregnancy: long-term effects on somatic growth, intellectual development and thyroid function of the offspring. Acta Endocrinol (Copenh) 1990; 123: 311–16.Google Scholar
Nakamura, S, Nishikawa, T, Isaji, M, et al. Aplasia cutis congenita and skull defects after exposure to methimazole in utero. Intern Med 2005; 44: 1202–3.Google Scholar
Karg, E, Bereg, E, Gaspar, L, et al. Aplasia cutis congenita after methimazole exposure in utero. Pediatr Dermatol 2004; 21: 491–4Google Scholar
Johansen, K, Andersen, AN, Kampmann, JP, et al. Excretion of methimazole in human milk. Eur J Clin Pharmacol 1982; 23: 339–41.Google Scholar
Cooper, DS. Antithyroid drugs: to breast-feed or not to breast-feed. Am J Obstet Gynecol 1987; 157: 234–5Google Scholar
Azizi, F, Bahrainian, M, Khamseh, ME, et al. Intellectual development and thyroid function in children who were breast-fed by thyrotoxic mothers taking methimazole. J Pediatr Endocrinol Metab 2003; 16: 1239–43.Google Scholar
Shepard, TH, Brent, RL, Friedman, JM, et al. Update on new developments in the study of human teratogens. Teratology 2002; 65: 153–61.Google Scholar
Suri, V, Sawhney, H, Vasishta, K, et al. Pregnancy following cardiac valve replacement surgery. Int J Gynaecol Obstet 1999; 64: 239–46.Google Scholar
Marks, PW. Management of thromboembolism in pregnancy. Semin Perinatol 2007; 31: 227–31.Google Scholar
Vitale, N, De Feo, M, Cotrufo, M. Anticoagulation for prosthetic heart valves during pregnancy: the importance of warfarin daily dose. Eur J Cardiothorac Surg 2002; 22: 656.Google Scholar
Hall, JG, Pauli, RM, Wilson, KM. Maternal and fetal sequelae of anticoagulation during pregnancy. Am J Med 1980; 68: 122–40.Google Scholar
Tyagi, A, Bhattacharya, A. Central neuraxial blocks and anticoagulation: a review of current trends. Eur J Anaesthesiol 2002; 19: 317–29.Google Scholar
Zakzouk, MS. The congenital warfarin syndrome. J Laryngol Otol 1986; 100: 215–19.Google Scholar
Wesseling, J, Van Driel, D, Smrkovsky, M, et al. Neurological outcome in school-age children after in utero exposure to coumarins. Early Hum Dev 2001; 63: 83–95.Google Scholar
Dardick, KR. Warfarin during lactation. Conn Med 1980; 44: 693.Google Scholar
Orme, ML, Lewis, PJ, de Swiet, M, et al. May mothers given warfarin breast-feed their infants? Br Med J 1977; 1: 1564–5.Google Scholar
Carney, SM, Goodwin, GM. Lithium—A continuing story in the treatment of bipolar disorder. Acta Psychiatr Scand Suppl 2005; 426: 7–12.Google Scholar
Viguera, AC, Nonacs, R, Cohen, LS, et al. Risk of recurrence of bipolar disorder in pregnant and nonpregnant women after discontinuing lithium maintenance. Am J Psychiatry 2000; 157: 179–84.Google Scholar
Gelenberg, AJ. Lithium efficacy and adverse effects. J Clin Psychiatry 1988; 49 (Suppl): 8–11.Google Scholar
Teixeira, NA, Lopes, RC, Secoli, SR. Developmental toxicity of lithium treatment at prophylactic levels. Braz J Med Biol Res 1995; 28: 230–9.Google Scholar
Pinelli, JM, Symington, AJ, Cunningham, KA, et al. Case report and review of the perinatal implications of maternal lithium use. Am J Obstet Gynecol 2002; 187: 245–9.Google Scholar
Giles, JJ, Bannigan, JG. Teratogenic and developmental effects of lithium. Curr Pharm Des 2006; 12: 1531–41.Google Scholar
Jacobson, SJ, Jones, K, Johnson, K, et al. Prospective multicentre study of pregnancy outcome after lithium exposure during first trimester. Lancet 1992; 339: 530–3.Google Scholar
Cohen, LS, Friedman, JM, Jefferson, JW, et al. A reevaluation of risk of in utero exposure to lithium. JAMA 1994; 271: 146–50.Google Scholar
van Gent, EM, Verhoeven, WM. Bipolar illness, lithium prophylaxis, and pregnancy. Pharmacopsychiatry 1992; 25: 187–91.Google Scholar
Poels EMP, Bijma HH, Galbally M, Bergink V. Lithium during pregnancy and after delivery: a review. Int J Bipolar Disord 2018; 6: 26. https://doi.org/10.1186/s40345-018-0135-7.Google Scholar
Newmark RL, Bogen DL, Wisner KL, et al. Risk-Benefit assessment of infant exposure to lithium through breast milk: a systematic review of the literature. Int Rev Psychiatry 2019; 31: 295–304. https://doi.org/10.1080/09540261.2019.1586657.Google Scholar
Viguera, AC, Newport, DJ, Ritchie, J, et al. Lithium in breast milk and nursing infants: Clinical implications. Am J Psychiatry 2007; 164: 342–5.Google Scholar
Eroglu, D, Oktem, M, Yanik, F, et al. Labor induction at term: a comparison of the effects of 50 microg and 25 microg vaginal misoprostol. Clin Exp Obstet Gynecol 2007; 34: 102–5.Google Scholar
Dodd, JM, Crowther, CA, Robinson, JS. Oral misoprostol for induction of labour at term: Randomised controlled trial. BMJ 2006; 332: 509–13.Google Scholar
Zikopoulos, KA, Papanikolaou, EG, Kalantaridou, SN, et al. Early pregnancy termination with vaginal misoprostol before and after 42 days gestation. Hum Reprod 2002; 17: 3079–83.Google Scholar
American College of Obstetrics and Gynecology. New U.S. Food and Drug Administration labeling on Cytotec (misoprostol) use and pregnancy (Committee Opinion. No. 283). Obstet Gynecol 2003; 10: 1049–50.Google Scholar
Alfirevic, Z, Weeks, A. Oral misoprostol for induction of labour. Cochrane Database Syst Rev. 2006; (2): CD001338.Google Scholar
Vogel, D, Burkhardt, T, Rentsch, K, et al. Misoprostol versus methylergometrine: Pharmacokinetics in human milk. Am J Obstet Gynecol 2004; 191: 2168–73Google Scholar
American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 206: Use of Hormonal Contraception in Women With Coexisting Medical Conditions. Obstet Gynecol 2019; 133: e128–50. https://doi.org/10.1097/AOG.0000000000003072.Google Scholar
Back, DJ, Breckenridge, AM, Crawford, F, et al. The effect of rifampicin on norethisterone pharmacokinetics. Eur J Clin Pharmacol 1979; 15: 193–7.Google Scholar
Nora, JJ, Nora, AH. Can the pill cause birth defects (editorial)? N Engl J Med 1974; 291: 731–2.Google Scholar
Jellesen, R, Andersen, AM. Prenatal exposure to birth control pills: Risk of fetal death and congenital malformations. Ugeskr Laeger 2006; 168: 2437–42.Google Scholar
Pardthaisong, T, Gray, RH. In utero exposure to steroid contraceptives and outcome of pregnancy. Am J Epidemiol 1991; 134: 795–803.Google Scholar
Yovich, JL, Turner, SR, Draper, R. Medroxyprogesterone acetate therapy in early pregnancy has no apparent fetal effects. Teratology 1988; 38: 135–44.Google Scholar
Abroms, L, Maibach, E, Lyon-Daniel, K, et al. What is the best approach to reducing birth defects associated with isotretinoin? PLoS Med 2006; 3: e483.Google Scholar
Brinker, A, Kornegay, C, Nourjah, P. Trends in adherence to a revised risk management program designed to decrease or eliminate isotretinoin-exposed pregnancies: evaluation of the Accutane SMART program. Arch Dermatol 2005; 141: 563–9.Google Scholar
Schaefer, C, Meister, R, Weber-Schoendorfer, C. Isotretinoin exposure and pregnancy outcome: an observational study of the Berlin Institute for Clinical Teratology and Drug Risk Assessment in Pregnancy. Arch Gynecol Obstet 2010; 281: 221–7.Google Scholar
Charakida, A, Mouser, PE, Chu, AC. Safety and side effects of the acne drug, oral isotretinoin. Expert Opin Drug Saf 2004; 3: 119–29.Google Scholar
Iagaru, A, McDougall, IR. Treatment of thyrotoxicosis. J Nucl Med 2007; 48: 379–89.Google Scholar
Pauwels, EK, Thomson, WH, Blokland, JA, et al. Aspects of fetal thyroid dose following iodine-131 administration during early stages of pregnancy in patients suffering from benign thyroid disorders. Eur J Nucl Med 1999; 26: 1453–7.Google Scholar
McClellan, DR, Francis, GL. Thyroid cancer in children, pregnant women, and patients with Graves’ disease. Endocrinol Metab Clin North Am 1996; 25: 27–48.Google Scholar
Smithells, RW, Newman, CG. Recognition of thalidomide defects. J Med Genet 1992; 29: 716–23.Google Scholar
Kastritis, E, Palumbo, A, Dimopoulos, MA. Treatment of relapsed/refractory multiple myeloma. Semin Hematol 2009; 46: 143–57.Google Scholar
Srinivasan, R, Akobeng, AK. Thalidomide and thalidomide analogues for induction of remission in Crohn’s disease. Cochrane Database Syst Rev 2009; (2): CD007350.Google Scholar
Panjwani, S. Early diagnosis and treatment of discoid lupus erythematosus. J Am Board Fam Med 2009; 22: 206–213.Google Scholar
Teo, SK, Harden, JL, Burke, AB, et al. Thalidomide is distributed into human semen after oral dosing. Drug Metab Dispos 2001; 29: 1355–7.Google Scholar
Holmes, LB. Teratogen-induced limb defects. Am J Med Genet 2002; 112: 297–303.Google Scholar
Rainsford, KD. Anti-inflammatory drugs in the 21st century. Subcell Biochem 2007; 42: 3–27.Google Scholar
Everson, GW, Krenzelok, EP. Chronic salicylism in a patient with juvenile rheumatoid arthritis. Clin Pharm 1986; 5: 334–41.Google Scholar
Li, DK, Liu, L, Odouli, R. Exposure to non-steroidal anti-inflammatory drugs during pregnancy and risk of miscarriage: Population based cohort study. BMJ 2003; 327: 368.Google Scholar
Kozer, E, Costei, AM, Boskovic, R, et al. Effects of aspirin consumption during pregnancy on pregnancy outcomes: meta-analysis. Birth Defects Res B Dev Reprod Toxicol 2003; 68: 70–84.Google Scholar
James, AH, Brancazio, LR, Price, T. Aspirin and reproductive outcomes. Obstet Gynecol Surv 2008; 63: 49–57.Google Scholar
Nadar, S, Blann, AD, Lip, GY. Effects of aspirin on intra-platelet vascular endothelial growth factor, angiopoietin-1, and p-selectin levels in hypertensive patients. Am J Hypertens 2006; 19: 970–7.Google Scholar
Empson, M, Lassere, M, Craig, JC, et al. Recurrent pregnancy loss with antiphospholipid antibody: a systematic review of therapeutic trials. Obstet Gynecol 2002; 99: 135–44.Google Scholar
Di Nisio, M, Peters, L, Middeldorp, S. Anticoagulants for the treatment of recurrent pregnancy loss in women without antiphospholipid syndrome. Cochrane Database Syst Rev 2005; (2): CD004734.Google Scholar
Farquharson, RG, Quenby, S, Greaves, M. Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. Obstet Gynecol 2002; 100: 408–13.Google Scholar
Caritis, S, Sibai, B, Hauth, J, et al. Low-dose aspirin to prevent preeclampsia in women at high risk. National Institute of Child Health and Human Development Network of Maternal–Fetal Medicine Units. N Engl J Med 1998; 338: 701–5.Google Scholar
Vainio, M, Kujansuu, E, Iso-Mustajarvi, M, et al. Low dose acetylsalicylic acid in prevention of pregnancy-induced hypertension and intrauterine growth retardation in women with bilateral uterine artery notches. BJOG 2002; 109: 161–7.Google Scholar
Bujold, E, Roberge, S, Nicolaides, KH. Low-dose aspirin for prevention of adverse outcomes related to abnormal placentation. Prenat Diagn. 2014; 34: 642–8.Google Scholar
Acetylcysteine (Acetadote) for acetaminophen overdosage. Med Lett Drugs Ther 2005; 47: 70–1.Google Scholar
Sunshine, A, Olson, NZ, O’Neill, E, et al. Analgesic efficacy of a hydrocodone with ibuprofen combination compared with ibuprofen alone for the treatment of acute postoperative pain. J Clin Pharmacol 1997; 37: 908–15.Google Scholar
Wiebe, ER, Rawling, M. Pain control in abortion. Int J Gynaecol Obstet 1995; 50: 41–6.Google Scholar
Anderson, DF, Phernetton, TM, Rankin, JH. The placental transfer of acetylsalicylic acid in near-term ewes. Am J Obstet Gynecol 1980; 136: 814–18.Google Scholar
Martinez-Frias, ML, Rodriguez-Pinilla, E, Prieto, L. Prenatal exposure to salicylates and gastroschisis: a case-control study. Teratology 1997; 56: 241–3.Google Scholar
Kirshon, B, Moise, KJ Jr, Wasserstrum, N. Effect of acetaminophen on fetal acid-base balance in chorioamnionitis. J Reprod Med 1989; 34: 955–9.Google Scholar
Golden, NL, King, KC, Sokol, RJ. Propoxyphene and acetaminophen: possible effects on the fetus. Clin Pediatr (Phila) 1982; 21: 752–4.Google Scholar
Adjei, AA, Gaedigk, A, Simon, SD, et al. Interindividual variability in acetaminophen sulfation by human fetal liver: implications for pharmacogenetic investigations of drug-induced birth defects. Birth Defects Res A Clin Mol Teratol 2008; 82: 155–65.Google Scholar
Collins, E. Maternal and fetal effects of acetaminophen and salicylates in pregnancy. Obstet Gynecol 1981; 58: 57S–62S.Google Scholar
Thomas, RL, Parker, GC, Van Overmeire, B, et al. A meta-analysis of ibuprofen versus indomethacin for closure of patent ductus arteriosus. Eur J Pediatr 2005; 164: 135–40.Google Scholar
Bar-Oz, B, Bulkowstein, M, Benyamini, L, et al. Use of antibiotic and analgesic drugs during lactation. Drug Saf 2003; 26: 925–35.Google Scholar
Bleyer, WA, Breckenridge, RT. Studies on the detection of adverse drug reactions in the newborn. II. The effects of prenatal aspirin on newborn hemostasis. JAMA 1970; 213: 2049–53.Google Scholar
Spigset, O, Hagg, S. Analgesics and breast-feeding: safety considerations. Paediatr Drugs 2000; 2: 223–38.Google Scholar
Mitchell, JL. Use of cough and cold preparations during breastfeeding. J Hum Lact 1999; 15: 347–9.Google Scholar
Watson-Jones, D, Gumodoka, B, Weiss, H, et al. Syphilis in pregnancy in Tanzania. II. The effectiveness of antenatal syphilis screening and single-dose benzathine penicillin treatment for the prevention of adverse pregnancy outcomes. J Infect Dis 2002; 186: 948–57.Google Scholar
Michelow, IC, Wendel, GD, Norgard, MV, et al. Central nervous system infection in congenital syphilis. N Engl J Med 2002; 346: 1792–8.Google Scholar
Ballard, RC, Berman, SM, Fenton, KA. Azithromycin versus penicillin for early syphilis. N Engl J Med 2006; 354: 203–5.Google Scholar
Boyer, KM, Gotoff, SP. Prevention of early-onset neonatal group B streptococcal disease with selective intrapartum chemoprophylaxis. N Engl J Med 1986; 314: 1665–9.Google Scholar
Stauffer, UG. Tooth changes caused by tetracycline in the fetus, infant and child. Schweiz Med Wochenschr 1967; 97: 291–3.Google Scholar
Bothamley, G. Drug treatment for tuberculosis during pregnancy: safety considerations. Drug Saf 2001; 24: 553–65.Google Scholar
Centers for Disease Control and Prevention (CDC). Updated recommendations for antimicrobial prophylaxis among asymptomatic pregnant women after exposure to Bacillus anthracis. MMWR Morb Mortal Wkly Rep 2001; 50: 960.Google Scholar
Ludlam, H, Wreghitt, TG, Thornton, S, et al. Q fever in pregnancy. J Infect 1997; 34: 75–8.Google Scholar
El-Tabbakh, GH, Elejalde, BR, Broekhuizen, F. Primary syphilis and nonimmune fetal hydrops in a penicillin-allergic woman. A case report. J Reprod Med 1994; 39: 412–14.Google Scholar
Smith, JR, Taylor-Robinson, D. Infection due to Chlamydia trachomatis in pregnancy and the newborn. Baillieres Clin Obstet Gynaecol 1993; 7: 237–55.Google Scholar
American College of Obstetricians and Gynecologists Committee on Adolescent Health Care. Sexually transmitted diseases in adolescents (Committee Opinion No. 30). Obstet Gynecol 2004; 104: 891–8.Google Scholar
Connell, W, Miller, A. Treating inflammatory bowel disease during pregnancy: risks and safety of drug therapy. Drug Saf 1999; 21: 311–23.Google Scholar
Gulmezoglu, AM. Interventions for trichomoniasis in pregnancy. Cochrane Database Syst Rev 2002; (3): CD000220.Google Scholar
Klebanoff, MA, Hauth, JC, MacPherson, CA, et al. Time course of the regression of asymptomatic bacterial vaginosis in pregnancy with and without treatment. Am J Obstet Gynecol 2004; 190: 363–70.Google Scholar
Klebanoff, MA, Hillier, SL, Nugent, RP, et al.; National Institute of Child Health and Human Development Maternal–Fetal Medicine Units Network. Is bacterial vaginosis a stronger risk factor for preterm birth when it is diagnosed earlier in gestation? Am J Obstet Gynecol 2005; 192: 470–7.Google Scholar
Okun, N, Gronau, KA, Hannah, ME. Antibiotics for bacterial vaginosis or Trichomonas vaginalis in pregnancy: a systematic review. Obstet Gynecol 2005; 105: 857–68.Google Scholar
Hauth, JC, Goldenberg, RL, Andrews, WW, et al. Reduced incidence of preterm delivery with metronidazole and erythromycin in women with bacterial vaginosis. N Engl J Med 1995; 333: 1732–6.Google Scholar
Carey, JC, Klebanoff, MA, Hauth, JC, et al. Metronidazole to prevent preterm delivery in pregnant women with asymptomatic bacterial vaginosis. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med 2000; 342: 534–40.Google Scholar
Goldenberg, RL, Klebanoff, M, Carey, JC, et al. Metronidazole treatment of women with a positive fetal fibronectin test result. Am J Obstet Gynecol 2001; 185: 485–6.Google Scholar
Klebanoff, MA, Carey, JC, Hauth, JC, et al. Failure of metronidazole to prevent preterm delivery among pregnant women with asymptomatic Trichomonas vaginalis infection. N Engl J Med 2001; 345: 487–93.Google Scholar
Shennan, A, Crawshaw, S, Briley, A, et al. A randomised controlled trial of metronidazole for the prevention of preterm birth in women positive for cervicovaginal fetal fibronectin: the PREMET Study. BJOG 2006; 113: 65–74.Google Scholar
McGregor, JA, French, JI. Bacterial vaginosis in pregnancy. Obstet Gynecol Surv 2000; 55(5 Suppl 1): S1–19.Google Scholar
Pacifici, GM. Placental transfer of antibiotics administered to the mother: a review. Int J Clin Pharmacol Ther 2006; 44: 57–63.Google Scholar
Elek, E, Ivan, E, Arr, M. Passage of penicillins from mother to foetus in humans. Int J Clin Pharmacol 1972; 6: 223–8.Google Scholar
Dashe, JS, Gilstrap, LC. Antibiotic use in pregnancy. Obstet Gynecol Clin North Am 1997; 24: 617–29.Google Scholar
Klastersky-Genot, MT. Effects of tetracycline, administered during pregnancy, on the deciduous teeth: a double blind controlled study. Acta Stomatol Belg 1970; 67: 107–24.Google Scholar
Czeizel, AE, Rockenbauer, M. Teratogenic study of doxycycline. Obstet Gynecol 1997; 89: 524–8.Google Scholar
Polachek, H, Holcberg, G, Sapir, G, et al. Transfer of ciprofloxacin, ofloxacin and levofloxacin across the perfused human placenta in vitro. Eur J Obstet Gynecol Reprod Biol 2005; 122: 61–5.Google Scholar
Berkovitch, M, Pastuszak, A, Gazarian, M, et al. Safety of the new quinolones in pregnancy. Obstet Gynecol 1994; 84: 535–8.Google Scholar
Peled, Y, Friedman, S, Hod, M, et al. Ofloxacin during the second trimester of pregnancy. DICP 1991; 25: 1181–2.Google Scholar
Heisterberg, L. Placental transfer of metronidazole in the first trimester of pregnancy. J Perinat Med 1984; 12: 43–5.Google Scholar
Nau, H. Clinical pharmacokinetics in pregnancy and perinatology. II. Penicillins. Dev Pharmacol Ther 1987; 10: 174–198.Google Scholar
Matheson, I, Samseth, M, Sande, HA. Ampicillin in breast milk during puerperal infections. Eur J Clin Pharmacol 1988; 34: 657–9.Google Scholar
Hendeles, L, Trask, P. Tetracycline and lactation. J Am Dent Assoc 1983; 107: 12, 14.Google Scholar
Giamarellou, H, Kolokythas, E, Petrikkos, G, et al. Pharmacokinetics of three newer quinolones in pregnant and lactating women. Am J Med 1989; 87: 49S–51S.Google Scholar
Harmon, T, Burkhart, G, Applebaum, H. Perforated pseudomembranous colitis in the breast-fed infant. J Pediatr Surg 1992; 27: 744–6.Google Scholar
Passmore, CM, McElnay, JC, Rainey, EA, et al. Metronidazole excretion in human milk and its effect on the suckling neonate. Br J Clin Pharmacol 1988; 26: 45–51.Google Scholar
Wendel, PJ, Ramin, SM, Barnett-Hamm, C, et al. Asthma treatment in pregnancy: a randomized controlled study. Am J Obstet Gynecol 1996; 175: 150–4.Google Scholar
Pongrojpaw, D, Somprasit, C, Chanthasenanont, A. A randomized comparison of ginger and dimenhydrinate in the treatment of nausea and vomiting in pregnancy. J Med Assoc Thai 2007; 90: 1703–9.Google Scholar
Aubé, M. Migraine in pregnancy. Neurology 1999; 53: S26–8.Google Scholar
Hay, TB, Wood, C. The effect of dimenhydrinate on uterine contractions. Aust N Z J Obstet Gynaecol 1967; 7: 81–9.Google Scholar
Andrade, SE, Raebel, MA, Brown, J, et al. Outpatient use of cardiovascular drugs during pregnancy. Pharmacoepidemiol Drug Saf 2008; 17: 240–7.Google Scholar
ACOG Task Force on Hypertension in Pregnancy. Hypertension in pregnancy: report of the American College of Obstetricians and Gynecologists. Obstet Gynecol 2013; 122: 1122–31.Google Scholar
Williamson, JD, Supiano, MA, Applegate, WB, et al.; SPRINT Research Group. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged ≥75 years: a randomized clinical trial. JAMA 2016; 315: 2673–82.Google Scholar
Borghi, C, Esposti, DD, Cassani, A, et al. The treatment of hypertension in pregnancy. J Hypertens Suppl 2002; 20: S52–6.Google Scholar
Kirsten, R, Nelson, K, Kirsten, D, Heintz, B. Clinical pharmacokinetics of vasodilators. Part II. Clin Pharmacokinet 1998; 35: 9–36.Google Scholar
Livingstone, I, Craswell, PW, Bevan, EB, et al. Propranolol in pregnancy three year prospective study. Clin Exp Hypertens B 1983; 2: 341–50.Google Scholar
Scardo, JA, Vermillion, ST, Newman, RB, et al. A randomized, double-blind, hemodynamic evaluation of nifedipine and labetalol in preeclamptic hypertensive emergencies. Am J Obstet Gynecol 1999; 181: 862–6.Google Scholar
Hennessy, A, Thornton, CE, Makris, A, et al. A randomised comparison of hydralazine and mini-bolus diazoxide for hypertensive emergencies in pregnancy: the PIVOT Trial. Aust N Z J Obstet Gynaecol 2007; 47: 279–85.Google Scholar
Vigil-De Gracia, P, Ruiz, E, López, JC, et al. Management of severe hypertension in the postpartum period with intravenous hydralazine or labetalol: a randomized clinical trial. Hypertens Pregnancy 2007; 26: 163–71.Google Scholar
Duley, L, Henderson-Smart, DJ, Meher, S. Drugs for treatment of very high blood pressure during pregnancy. Cochrane Database Syst Rev 2006; (3): CD001449.Google Scholar
Caswell, HT, Marks, AD, Channick, BJ. Propranolol for the preoperative preparation of patients with thyrotoxicosis. Surg Gynecol Obstet 1978; 146: 908–10.Google Scholar
Sukenik, S, Biale, Y, Ben-Aderet, N, et al. Successful control of pheochromocytoma in pregnancy. Eur J Obstet Gynecol Reprod Biol 1979; 9: 249–51.Google Scholar
Bott-Kanner, G, Schweitzer, A, Reisner, SH, et al. Propranolol and hydrallazine in the management of essential hypertension in pregnancy. Br J Obstet Gynaecol 1980; 87: 110–14.Google Scholar
Elhassan, EM, Mirghani, OA, Habour, AB, et al. Methyldopa versus no drug treatment in the management of mild pre-eclampsia. East Afr Med J 2002; 79: 172–5.Google Scholar
Gunenc, O, Cicek, N, Gorkemli, H, et al. The effect of methyldopa treatment on uterine, umblical and fetal middle cerebral artery blood flows in preeclamptic patients. Arch Gynecol Obstet 2002; 266: 141–4.Google Scholar
Houlihan, DD, Dennedy, MC, Ravikumar, N, et al. Anti-hypertensive therapy and the feto-placental circulation: effects on umbilical artery resistance. J Perinat Med 2004; 32: 315–19.Google Scholar
Olsen, KS, Beier-Holgersen, R. Fetal death following labetalol administration in pre-eclampsia. Acta Obstet Gynecol Scand 1992; 71: 145–7.Google Scholar
Crooks, BN, Deshpande, SA, Hall, C, et al. Adverse neonatal effects of maternal labetalol treatment. Arch Dis Child Fetal Neonatal Ed 1998; 79: F150–1.Google Scholar
Hjertberg, R, Faxelius, G, Belfrage, P. Comparison of outcome of labetalol or hydralazine therapy during hypertension in pregnancy in very low birth weight infants. Acta Obstet Gynecol Scand 1993; 72: 611–15.Google Scholar
Bowman, ML, Bergmann, M, Smith, JF. Intrapartum labetalol for the treatment of maternal and fetal thyrotoxicosis. Thyroid 1998; 8: 795–6.Google Scholar
Beardmore, KS, Morris, JM, Gallery, ED. Excretion of antihypertensive medication into human breast milk: a systematic review. Hypertens Pregnancy 2002; 21: 85–95.Google Scholar
Munshi, UK, Deorari, AK, Paul, VK, et al. Effects of maternal labetalol on the newborn infant. Indian Pediatr 1992; 29: 1507–12.Google Scholar
Reichmuth, D, Lockey, RF. Present and potential therapy for allergic rhinitis: a review. BioDrugs 2000; 14: 371–87.Google Scholar
Chanda, M, Mackenzie, P, Day, JH. Hypersensitivity reactions following laminaria placement. Contraception 2000; 62: 105– 6.Google Scholar
Stafford, CT, Lobel, SA, Fruge, BC, et al. Anaphylaxis to human serum albumin. Ann Allergy 1988; 61: 85–8.Google Scholar
Miller, AA. Diphenhydramine toxicity in a newborn: a case report. J Perinatol 2000; 20: 390–1.Google Scholar
American College of Obstetrics and Gynecology. Management of herpes in pregnancy (Practice Bulletin No. 82). Obstet Gynecol 2007; 109: 1489–98.Google Scholar
Scott, LL, Hollier, LM, McIntire, D, et al. Acyclovir suppression to prevent recurrent genital herpes at delivery. Infect Dis Obstet Gynecol 2002; 10: 71–7.Google Scholar
Little, SE, Caughey, AB. Acyclovir prophylaxis for pregnant women with a known history of herpes simplex virus: a cost-effectiveness analysis. Am J Obstet Gynecol 2005; 193: 1274–9.Google Scholar
Kimberlin, DF, Weller, S, Whitley, RJ, et al. Pharmacokinetics of oral valacyclovir and acyclovir in late pregnancy. Am J Obstet Gynecol 1998; 179: 846–51.Google Scholar
Laerum, OD. Toxicology of acyclovir. Scand J Infect Dis Suppl 1985; 47: 40–3.Google Scholar
Sheffield, JS, Fish, DN, Hollier, LM, et al. Acyclovir concentrations in human breast milk after valaciclovir administration. Am J Obstet Gynecol 2002; 186: 100–2.Google Scholar
Silver, RK, MacGregor, SN, Sholl, JS, et al. Comparative trial of prednisone plus aspirin versus aspirin alone in the treatment of anticardiolipin antibody-positive obstetric patients. Am J Obstet Gynecol 1993; 169: 1411–17.Google Scholar
Lieman, JM, Brumfield, CG, Carlo, W, et al. Preterm premature rupture of membranes: Is there an optimal gestational age for delivery? Obstet Gynecol 2005; 105: 12–17Google Scholar
Walfisch, A, Hallak, M, Mazor, M. Multiple courses of antenatal steroids: Risks and benefits. Obstet Gynecol 2001; 98: 491–7.Google Scholar
Garite, TJ, Kurtzman, J, Maurel, K, et al.; Obstetrix Collaborative Research Network. Impact of a “rescue course” of antenatal corticosteroids: a multicenter randomized placebo-controlled trial. Am J Obstet Gynecol 2009; 200: 248.e1–9.Google Scholar
Egerman, RS, Mercer, BM, Doss, JL, et al. A randomized, controlled trial of oral and intramuscular dexamethasone in the prevention of neonatal respiratory distress syndrome. Am J Obstet Gynecol 1998; 179: 1120–3.Google Scholar
Gurbuz, A, Karateke, A, Ozturk, G, et al. Is 1-hour glucose screening test reliable after a short-term administration of antenatal betamethasone? Am J Perinatol 2004; 21: 415–20.Google Scholar
Elliott, JP, O’Keeffe, DF, Greenberg, P, et al. Pulmonary edema associated with magnesium sulfate and betamethasone administration. Am J Obstet Gynecol 1979; 134: 717–19.Google Scholar
Mushkat, Y, Ascher-Landsberg, J, Keidar, R, et al. The effect of betamethasone versus dexamethasone on fetal biophysical parameters. Eur J Obstet Gynecol Reprod Biol 2001; 97: 50–2.Google Scholar
Wapner, RJ, Sorokin, Y, Thom, EA, et al.; National Institute of Child Health and Human Development Maternal Fetal Medicine Units Network. Single versus weekly courses of antenatal corticosteroids: Evaluation of safety and efficacy. Am J Obstet Gynecol 2006; 195: 633–42.Google Scholar
Fujii, Y, Uemura, A. Dexamethasone for the prevention of nausea and vomiting after dilatation and curettage: A randomized controlled trial. Obstet Gynecol 2002; 99: 58–62.Google Scholar
Martin, JN, Thigpen, BD, Rose, CH, et al. Maternal benefit of high-dose intravenous corticosteroid therapy for HELLP syndrome. Am J Obstet Gynecol 2003; 189: 830–4.Google Scholar
Fonseca, JE, Mendez, F, Catano, C, et al. Dexamethasone treatment does not improve the outcome of women with HELLP syndrome: a double-blind, placebo-controlled, randomized clinical trial. Am J Obstet Gynecol 2005; 193: 1591–8.Google Scholar
Addison, RS, Maguire, DJ, Mortimer, RH, et al. Metabolism of prednisolone by the isolated perfused human placental lobule. J Steroid Biochem Mol Biol 1991; 39: 83–90.Google Scholar
Lockshin, MD, Sammaritano, LR. Corticosteroids during pregnancy. Scand J Rheumatol Suppl 1998; 107: 136–8.Google Scholar
Walker, BE. Induction of cleft palate in rats with antiinflammatory drugs. Teratology 1971; 4: 39–42.Google Scholar
Park-Wyllie, L, Mazzotta, P, Pastuszak, A, et al. Birth defects after maternal exposure to corticosteroids: Prospective cohort study and meta-analysis of epidemiological studies. Teratology 2000; 62: 385–92.Google Scholar
Carmichael, SL, Shaw, GM, Ma, C, et al.; National Birth Defects Prevention Study. Maternal corticosteroid use and orofacial clefts. Am J Obstet Gynecol 2007; 197: 585.e1–7.Google Scholar
Effect of corticosteroids for fetal maturation on perinatal outcomes. NIH Consens Statement 1994; 12 (2): 1–24.Google Scholar
Spinillo, A, Viazzo, F, Colleoni, R, et al. Two-year infant neurodevelopmental outcome after single or multiple antenatal courses of corticosteroids to prevent complications of prematurity. Am J Obstet Gynecol 2004; 191: 217–24.Google Scholar
Huang, WL, Harper, CG, Evans, SF, et al. Repeated prenatal corticosteroid administration delays myelination of the corpus callosum in fetal sheep. Int J Dev Neurosci 2001; 19: 415–25.Google Scholar
Whitelaw, A, Thoresen, M. Antenatal steroids and the developing brain. Arch Dis Child Fetal Neonatal Ed 2000; 83: F154–7.Google Scholar
Rotmensch, S, Lev, S, Kovo, M, et al. Effect of betamethasone administration on fetal heart rate tracing: a blinded longitudinal study. Fetal Diagn Ther 2005; 20: 371–6.Google Scholar
Hayes, EJ, Paul, DA, Stahl, GE, et al. Effect of antenatal corticosteroids on survival for neonates born at 23 weeks of gestation. Obstet Gynecol 2008; 111: 921–6.Google Scholar
American College of Obstetricians and Gynecologists, Committee Opinion: Antenatal corticosteroid therapy for fetal maturation. Obstet Gynecol 2002; 99: 871–3.Google Scholar
Mulder, EJ, Derks, JB, Visser, GH. Antenatal corticosteroid therapy and fetal behaviour: a randomised study of the effects of betamethasone and dexamethasone. Br J Obstet Gynaecol 1997; 104: 1239–47.Google Scholar
Costedoat-Chalumeau, N, Georgin-Lavialle, S, Amoura, Z, et al. Anti-SSA/Ro and anti-SSB/La antibody-mediated congenital heart block. Lupus 2005; 14: 660–4.Google Scholar
Hughes, I. Prenatal treatment of congenital adrenal hyperplasia: Do we have enough evidence? Treat Endocrinol 2006; 5: 1–6.Google Scholar
Brook, CG. Antenatal treatment of a mother bearing a fetus with congenital adrenal hyperplasia. Arch Dis Child Fetal Neonatal Ed 2000; 82: F176–81.Google Scholar
Leman, J, Burden, A. Treatment of severe psoriasis with infliximab. Ther Clin Risk Manag 2008; 4: 1165–76.Google Scholar
Teshima, CW, Thompson, A, Dhanoa, L, et al. Long-term response rates to infliximab therapy for Crohn’s disease in an outpatient cohort. Can J Gastroenterol 2009; 23: 348–52.Google Scholar
Allaart, CF, Breedveld, FC, Dijkmans, BA. Treatment of recent-onset rheumatoid arthritis: lessons from the BeSt Study. J Rheumatol Suppl 2007; 80: 25–33.Google Scholar
O’Donnell, S, O’Morain, C. Use of antitumour necrosis factor therapy in inflammatory bowel disease during pregnancy and conception. Aliment Pharmacol Ther 2008; 27: 885–94.Google Scholar
Mahadevan, U, Sandborn, WJ, Li, DK, et al. Pregnancy outcomes in women with inflammatory bowel disease: a large community-based study from Northern California. Gastroenterology 2007; 133: 1106–12.Google Scholar
Roux, CH, Brocq, O, Breuil, V, et al. Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)-alpha therapy. Rheumatology (Oxford) 2007; 46: 695–8.Google Scholar
Stengel, JZ, Arnold, HL. Is infliximab safe to use while breastfeeding? World J Gastroenterol 2008; 14: 3085–7.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×